Remember Spirocor, the Israeli company that closed down a clinical trial involving its “respiratory stress” test for coronary artery disease because the data underpinning the validity of the method proved unreliable? The problem led to the retraction of two articles, about which we’ve previously reported. But we also found a study by some of the same researchers, who include scientists in Israel and the United States, that had been presented at the 2010 meeting of the American Heart Association and published in the journal Circulation.
That abstract, No. 14426 “Accuracy and Usefulness of Finger Pulse Wave Analysis during Brief Deep Breathing Exercise (Respiratory Stress Response) as a Marker of Significant Coronary Artery Disease,” has now been retracted — making, to our knowledge, the entire body of published research on the Spirocor product an editorial memory.
Here’s the notice, which appears within the text of the abstract: Continue reading Another retraction of Spirocor research
Since we first wrote about the travails of Spirocor’s bedside, noninvasive test for coronary artery disease, we’ve been trying, without much success, to find out more information.
But as they say about every dog, our day has come.
As we initially reported, Ron Waksman, a prominent Washington, D.C. cardiologist and editor-in-chief of Cardiovascular
and Revascularization Medicine, was first author of one of two papers about the Spirocor technology that were published in 2010. The other, by Shiyovich, et al, was retracted earlier this month by the American Journal of the Medical Sciences, which triggered our interest in this case.
At the time, we couldn’t find any evidence that Waksman’s article had been retracted, and Waksman has not responded to multiple requests for comment. Today we spoke with Kate Coons, the journal’s managing editor, who told us that the authors had sought a retraction for the article, “An innovative noninvasive respiratory stress test indicates significant coronary artery disease,” in December, and that it had posted one on its website on Jan. 6 of this year. It will be in print in an upcoming issue.
The notice is not available on Medline, but it can be found on ScienceDirect: Continue reading More on SPIROCOR noninvasive heart disease test: Second retraction (in fact the first) says little
A retraction in an obscure journal. An equally obscure retraction notice. An Israeli company with no web presence. Conflicts of interest involving authors and editors.
That’s what we’ve uncovered so far after noticing the other day that the American Journal of the Medical Sciences (AJMS) had retracted a May 2010 article by a group of Israeli heart doctors led by Arthur Shiyovich, of Barzilai Medical Center in Ashkelon.
The paper described promising results in a study of a new test for diagnosing coronary artery disease at the bedside by measuring aspects of a patient’s pulse at the fingertip.
As AJMS editor David Ploth told us, the approach had seemed “kind of innovative” to him, so he’d accepted the manuscript: “It seemed like it might have some applicability.”
Ploth was therefore surprised sometime later to receive a letter from the authors requesting that the journal retract their paper. According to the journal: Continue reading Tangled leads: Cardiac study retraction reveals a company’s stopped trials, and lots of questions